Leader in cancer prevention, detection, treatment & research. @IcahnMountSinai & @MountSinaiNYC Appointments: 1-844-MD CANCER
New York, NY
- Tweets 7,827
- Following 953
- Followers 4,444
- Likes 1,993
.@myelomatips presents tomorrow at #IMS26: “Etentamig Combined With Pomalidomide Plus Dexamethasone in Relapsed/Refractory #MultipleMyeloma After 1-3 Prior Lines of Therapy: A Phase 1b Dose-Escalation and Safety Expansion Study”
@IcahnMountSinai @Myeloma_Society
2
2
301
Mount Sinai Study Identifies Why Some Patients Develop Severe Intestinal Inflammation After CAR-T Therapy | Newswise newswise.com/articles/mount-…
Samir Parekh, MBBS; Saurabh Mehandru, MD; Nikhit Kethidi, MD @IcahnMountSinai #MultipleMyeloma
3
149
Adolfo Aleman presents on Sep 26 at #IMS26:
“Persistent Mucosal CAR-T Cells & Interferon-Driven Inflammation Drive BCMA-Targeted CAR-T Therapy–Associated Enterocolitis”
“Iberdomide Priming Enhances Anti-BCMA CAR-T Efficacy in #MultipleMyeloma”
@IcahnMountSinai @Myeloma_Society
2
1
262
.@Zach_Avigan presents today at #IMS26: “Predicting Cure in Myeloma: Sustained MRD Dynamics, Genomic Risk, and ISS Define Ultra-Low-Risk Subgroup With Favorable Outcomes After Stopping Therapy”
#MultipleMyeloma #MMSM @IcahnMountSinai
1
2
10
519
Free screening for #prostatecancer is availalbe at Richmond County Family Court, Staten Island, on Monday, September 28. No appointment needed.
#ProstateCancerAwarenessMonth
@MountsinaiUro @AshTewariMD
2
169
Mount Sinai Tisch Cancer Center retweeted
Samir Parekh giving a master class on: Immune markers of disease activity At #IMS26 #mmsm @TischCancer @Myeloma_Society
16
30
1,513
New in @NatureMedicine: Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy
rdcu.be/hJYF5JAFR1ha
@MehandruLab and Samir Parekh @IcahnMountSinai and colleagues
1
3
293
Natasha Kyprianou, PhD, is pleased to welcome two postdocs to her lab at @IcahnMountSinai:
Prateek Kulkarni, PhD, and Kyle Greenland, PhD
Dr. Kyprianou investigates mechanisms of therapeutic resistance in advanced prostate, bladder and kidney cancers.
profiles.icahn.mssm.edu/nata…
1
5
466
.@FionnualaCrowle on the Palliative Care Gap in Oncology medpagetoday.com/reading-roo…
@IcahnMountSinai
2
6
3,099
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
From Lakshmi Rajdev, MD, MS, and colleagues
@luckydoc2 @IcahnMountSinai
1
279
A new AI-powered test offers more accurate prediction of breast cancer recurrence risk medicalxpress.com/news/2026-… via @medical_xpress
@jsparano, @IcahnMountSinai, is lead author. #BreastCancer
1
4
455
Pei Wang, PhD, and colleagues have identified candidate treatment targets and potential prognostic markers for high-grade glioma.
mountsinai.org/about/newsroo…
@IcahnMountSinai #glioma
3
7
853
We look forward to hearing from David Christiani, MD, MPS, MS on September 22:
"Environmental Determinants of Lung Cancer Survival"
Hosted by @ZeynepHG, @IcahnMountSinai
#LungCancer
1
2
235
Noah Osei, MD, @IcahnMountSinai, presented
Barriers to Enrollment to a Clinical Trial for Frail Patients With Advanced Non-Small Cell Lung Cancer at @IASLC #WCLC26
cattendee.abstractsonline.co…
@FionnualaCrowle @fred_hirsch @DDoroshow #LungCancer
5
717
.@RajaFlores says oncology is loose with staging jargon, and now “it’s co... piped.video/j92b0MAaCIg?si=sZrQ… via @YouTube
@IcahnMountSinai #LungCancer
1
2
438
Congratulations to @Moe_ByrneMD, winner of the women's event at the Tell Every Amazing Lady® Brooklyn 5K Fun Run on September 12.
Dr. Byrne is joining @IcahnMountSinai in the Division of Gynecologic Oncology in October.
#OvarianCancer #OvarianCancerAwarenessMonth
@TEALWALK
2
3
260
Mount Sinai Tisch Cancer Center retweeted
@nh_osei presents his poster highlighting that tumors with MET exon 14 mutations and tumors with MET amplification have distinct clinicopathlogic profiles. #WCLC26 @TischCancer @fred_hirsch
4
11
1,418